National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities.

Worasuda Yoongthong,Shanlian Hu,Jennifer A Whitty,Suwit Wibulpolprasert,Kitti Sukantho,Wannisa Thienthawee,Huixue Han,Paul A Scuffham
DOI: https://doi.org/10.1016/j.jval.2011.11.003
IF: 5.156
2012-01-01
Value in Health
Abstract:This commentary is aimed at summarizing the second plenary session presented at the ISPOR 4th Asia-Pacific Conference held in 2010 and compare the issues on drug listing of Thailand, China, and Australia. These countries have substantially different demographic and economic characteristics and health-care financing structures and are in different phases of development of health technology assessment (HTA) (Table 1). Expenditure data shown in Table 1 for 2008 were converted at purchasing power parity to US dollars.
What problem does this paper attempt to address?